Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Worldwide Stock Indices Sample helps you grasp how global benchmarks reflect market trends. This intro explains key components and practical uses in everyday investing.
16,517 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Palantir just beat earnings, yet its stock fell in after-hours trading as traders priced in slower growth and macro h...
SpaceX's IPO is on the horizon, but you can gain exposure today through a strategic backdoor. This article explains w...
As Uber eyes profitability, a multi-year bull case hinges on margin expansion and stronger bookings. This analysis ou...
This article breaks down egain (egan) 2026 earnings with a clear, data-driven view. We examine revenue drivers, margi...
Beyond Meat faces headwinds, but a protein drinks turnaround catalyst could change the game. This article breaks down...
The AI boom isn’t over. If you felt you missed the first wave, these three resilient stocks deliver real AI leverage,...
A major hedge fund exit grabbed headlines as a fund controlled by William Oberndorf liquidated a sizable monday.com s...
Netflix is trading near its 52-week low as ad-supported growth and cash flow gains reshape investor bets. Analysts di...
In May, iren limited rallied almost 40% as investors priced in AI growth, earnings signals, and a new Nvidia partners...
Investors are watching Duluth Trading closely as the Q1 2026 earnings cycle begins. This in-depth look breaks down wh...
Altria sits around $73 with a near-6% yield, yet a from 52-week low: glaring risk and consumer softness raise questio...